Regeneron Pharmaceuticals Stock Price, News & Analysis (NASDAQ:REGN)

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.

26 equities research analysts have issued 12-month target prices for Regeneron Pharmaceuticals' stock. Their REGN share price targets range from $680.00 to $1,050.00. On average, they expect the company's share price to reach $903.52 in the next year. This suggests a possible upside of 11.7% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.

Regeneron Pharmaceuticals' stock was trading at $721.49 on January 1st, 2023. Since then, REGN shares have increased by 12.1% and is now trading at $808.59.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, February 2nd 2024.
View our REGN earnings forecast.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Thursday, November, 2nd. The biopharmaceutical company reported $10.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.39 by $0.78. The biopharmaceutical company had revenue of $3.36 billion for the quarter, compared to analyst estimates of $3.23 billion. Regeneron Pharmaceuticals had a net margin of 30.47% and a trailing twelve-month return on equity of 18.61%. Regeneron Pharmaceuticals's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $9.98 EPS.
Read the conference call transcript.

ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA), American CenturyFocused Dynamic Growth ETF (FDG) and Subversive Mental Health ETF (SANE).

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (9.03%), Loomis Sayles & Co. L P (1.14%), Northern Trust Corp (0.98%), Morgan Stanley (0.89%), Bank of New York Mellon Corp (0.89%) and Legal & General Group Plc (0.75%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends.

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.